The global macular degeneration treatment market size was valued at USD 10.06 billion in 2024 and it is projected to reach ...

DelveInsight's 'Dry Age-Related Macular Degeneration Pipeline Insight 2025' report provides comprehensive global coverage of ...

Macular degeneration is a leading cause of vision loss for people over 50, but there are ways to help protect your eyesight.

Introduction The eye's macula is impacted by macular degeneration, a neurodegenerative condition. Macular degeneration will cause loss of centr ...

Dry macular degeneration is a common eye disorder among people aged above 50 years. It causes blurred or reduced central vision due to thinning of the macula. The macula is the part of the retina ...

Medication is sometimes necessary to treat eye conditions and vision problems. Of course, this is highly dependent on the ...

Lower rates of both progression of macular fibrosis and intravitreal aflibercept injections were found in those who used the ...

SBL03 was formulated as an ophthalmic gel for non-invasive topical delivery. Its unique ability to infiltrate eye tissues effectively and protect ret ...

It is a good test for screening for the development of "wet" macular degeneration in patients with "dry" macular degeneration.

In October, Oxular began a phase 2 trial for its therapeutic candidate OXU-001, for treatment of diabetic macular edema ...

The FDA has granted RMAT designation to Beacon Therapeutics’ gene therapy, laru-zova, for treating X-linked retinitis pigmentosa (XLRP).

Naples, Italy-based rare diseases focused biotech BIOVIIIx says that its subsidiary Anbition and Japanese firm TagCyx ...